pharmanucleus1

[pharmanucleus1]

Chronic Pancreatitis Market: Advanced Therapies & Insights

Chronic Pancreatitis Market

Market Overview

The chronic pancreatitis market is expected to grow at a CAGR of 5.70% during the forecast period of 2023 to 2030. The growth of the market is attributed to the rising prevalence of pancreatic disorders globally, increasing incidence of alcohol-induced pancreatitis, and growing demand for minimally invasive surgical procedures.

Click here for full report:

https://www.pharmanucleus.com/reports/chronic-pancreatitis-market

Market Dynamics

The global chronic pancreatitis market is expected to register a stable revenue CAGR during the forecast period. The chronic pancreatitis market revenue growth is primarily driven by the increasing prevalence of pancreatic disorders globally.

Chronic pancreatitis is a painful inflammation of the pancreatic tissue, which can lead to lesions of the glands characterized by fibrosis, ductal inflammation and calcification. Inflammation of pancreatic tissue can lead to inability to digest food, interferes with enzyme and hormone production, and sugar regulation. Chronic pancreas is an autoimmune disease that can occur due to mistaken attack of healthy cells and tissues. Other causes of chronic pancreatitis are gallstones or pancreatic stones, cystic fibrosis, hypercalcemia and hypertriglyceridemia. Symptoms of chronic pancreatitis are abdominal pain, fatty stools, nausea, vomiting, shortness of breath, excessive thirst, and fatigue.

Drivers:

Rising prevalence of chronic pancreatitis due to rise in unhealthy lifestyles like excessive alcohol consumption and smoking in the growing population is one of the major factors driving the revenue growth of the market. chronic pancreatitis.

The increase in chronic diseases such as diabetes and malnutrition increases the risk of organ failure and contributes to the revenue growth of the chronic pancreatitis market.

Technological advancements in the treatment of chronic pancreatitis, increase in research and development of drugs for the treatment are supporting the revenue growth of chronic pancreatitis market.

Restraints:

The high cost of current chronic pancreatitis therapy and a lack of awareness about treatment and symptoms in low-income countries are the key factors limiting revenue development in the chronic pancreatitis industry.

Post COVID Impact

The COVID-19 pandemic has had a significant impact on various aspects of healthcare, including the treatment and management of chronic pancreatitis. Chronic pancreatitis, a long-term inflammation of the pancreas, is a debilitating condition that requires ongoing medical intervention. Here are some key post-COVID-19 impacts on the chronic pancreatitis market:

Delayed diagnoses: Due to the diversion of healthcare resources towards managing the pandemic, many non-emergency procedures and appointments were postponed or canceled. As a result, the diagnosis of chronic pancreatitis may have been delayed, leading to a backlog of cases and potentially worsening patient outcomes.

Disruption in treatment access: Lockdowns, travel restrictions, and overwhelmed healthcare systems have hindered patients' access to regular medical care, including medications, diagnostic tests, and surgical interventions. This disruption may have led to suboptimal disease management and increased complications among chronic pancreatitis patients.

Click here for full report:

https://www.pharmanucleus.com/reports/chronic-pancreatitis-market

Increased telemedicine adoption: The pandemic accelerated the adoption of telemedicine as a means of providing remote healthcare services. For chronic pancreatitis patients, telemedicine has facilitated virtual consultations, monitoring, and prescription refills, ensuring continuous care and reducing the risk of exposure to the virus.

Focus on minimally invasive procedures: In the wake of the pandemic, there has been a shift towards less invasive procedures and interventions. This may benefit chronic pancreatitis patients, as minimally invasive techniques can potentially reduce hospital stays, minimize infection risks, and speed up recovery.

Emphasis on patient self-management: With limited access to healthcare facilities, chronic pancreatitis patients have been encouraged to take a more active role in self-management. This includes adhering to dietary guidelines, lifestyle modifications, and monitoring symptoms at home. Increased patient education and support systems have been crucial in empowering individuals to manage their condition effectively.

In conclusion, the COVID-19 pandemic has presented several challenges and changes in the chronic pancreatitis market. While delayed diagnoses and treatment disruptions have posed obstacles, the adoption of telemedicine, emphasis on self-management, and focus on minimally invasive procedures have provided opportunities for improved patient care in the post-COVID era.

Opportunities:

The forecast period is anticipated to bring lucrative growth opportunities due to various factors. Technological advancements in treating chronic pancreatitis, along with improved healthcare facilities, research, and drug development, are contributing to the positive outlook. Government initiatives aimed at spreading awareness about symptoms and available treatments are also playing a crucial role. Furthermore, increased investments in healthcare are expected to further drive growth in the sector. Overall, these factors together create a favorable environment for the expansion of treatments and advancements in managing chronic pancreatitis.

Click here for request free sample report:

https://www.pharmanucleus.com/request-sample/1199

Geographic Market Scenario Largest Market Share:

With the biggest revenue share, North America has emerged as the largest regional market for chronic pancreatitis. Revenue increase can be ascribed to a variety of causes, including growing healthcare expenditure in the region. Additionally, rising awareness of chronic pancreatitis, as well as an increase in its occurrence, are contributing to revenue growth. Significant advances in North America's healthcare industry are supporting the market's bullish outlook. These variables, taken together, establish North America as a prominent market for chronic pancreatitis therapy, contributing to the region's leading revenue share.

Fastest Growing Market:

The chronic pancreatitis market in the Asia Pacific region is projected to experience rapid growth during the forecast period. Several factors contribute to this growth, including the increasing number of patients diagnosed with chronic pancreatitis. Government initiatives aimed at raising awareness about the condition further support the market's revenue growth in the region. Additionally, the growing demand for treatment options drives market expansion. The presence of a large population in the Asia Pacific region is also expected to have a positive impact on the revenue growth of the chronic pancreatitis market. With a significant pool of potential patients, the market is poised to witness lucrative opportunities for pharmaceutical companies, healthcare providers, and other stakeholders operating in the region. The Asia Pacific region is emerging as a vital market for chronic pancreatitis treatment, offering substantial growth potential.

[pharmanucleus1]

Chronic Lymphocytic Leukemia Market: Breakthroughs & Care Innovations

Market Overview

The market size for treatments for chronic lymphocytic leukaemia was estimated at USD 4.9 billion in 2023. The market for treating chronic lymphocytic leukaemia is anticipated to increase from USD 5.3 billion in 2023 to USD 8.68 billion in 2030, with a compound annual growth rate (CAGR) of 8.52% over the five-year forecast period (2023–2030). greater leukaemia incidence, a sizable unmet medical need for cancer therapy, hereditary blood abnormalities, and greater investment in the healthcare industry are the main major factors boosting the market share of chronic lymphocytic leukaemia treatments.

Click here for full report:

https://www.pharmanucleus.com/reports/chronic-lymphocytic-leukemia-market

Market Trends

The growing prevalence of chronic lymphocytic leukemia drives the market growth

Chronic lymphocytic leukemia (CLL) is a cancer affecting the white blood cells. Radiation therapy, chemotherapy, and stem cell transplants are possible treatments for CLL. CLL treatment is essential because it can help improve symptoms and increase life expectancy. In India, there are one million new cases of chronic lymphocytic leukemia diagnosed every year, according to an article written by Apollo Hospitals. According to cancer statistics, one in 155 men and one in 260 women in England suffer from chronic lymphocytic leukaemia. Leukemia affects a large part of the world's population. Leukemia is diagnosed by acute and chronic illnesses caused by exposure to radiation, poor lifestyle choices and environmental factors. According to the 2021 Leukemia& Lymphoma Society study, men are affected by leukemia at a rate of approximately 36.5%. Men are diagnosed with and die of leukemia more often than women. Additionally, leukemia affected people of all genders and ages, with 474,519 cases worldwide in 2020, according to GLOBOCAN 2021 statistics. According to the same source, leukemia was one of the leading causes of death in the world in 2020. As a result, global data indicates that a significant population is susceptible to leukemia, which could positively impact the growth of chronic lymphocytic leukemia CAGR. processing market over the projection period. .

The market is expected to be impacted by the growth of the biotechnology sector, advancements in medication discovery, and increased R&D spending. As an illustration, to hasten the development of newer and more effective immunotherapies for the treatment of blood malignancies, the Leukaemia & Lymphoma Society's Therapy Acceleration Programme announced five new investments in April 2021. As a consequence of R&D and the launch of new products by a number of firms, the market is anticipated to expand.For instance, the National Cancer Institute (NCI) and Mayo Clinic will team up on a Phase I study on September 22, 2023, to evaluate the safety, effectiveness, and ideal dose of Onvansertib for the treatment of persons with leukaemia. either non-responsive or prone to relapse. The PLK1 enzyme is bound to by onvansertib and inhibited, which stunts the development of cancer cells and harms healthy cells. As a consequence of product development activities and product launches, the market revenue for therapeutics for chronic lymphocytic leukaemia is rising.

Segment Insights

Based on types, chronic lymphocytic leukemia treatment market segmentation includes indolent, aggressive and others. The indolent segment held the majority share in 2023, contributing around 65-67% of chronic lymphocytic leukemia treatment market revenue. The growth of the indolent segment of the chronic lymphocytic leukemia treatment market is mainly driven by the increase in the incidence of comorbidities, especially in the elderly, and the introduction of new drugs in development. Indolent chronic lymphocytic leukemia grows slowly and can remain stable for years without treatment. If the chronic lymphocytic leukemia is indolent, the blood count of other blood cells is average or slightly below average, even if more lymphocytes are present. With approximately 20,000 new cases expected to be diagnosed in 2023, Chinese society is aware of chronic lymphocytic leukemia. This indolent B-cell malignancy is the most common adult leukemia in the United States.

Click here for full report:

https://www.pharmanucleus.com/reports/chronic-lymphocytic-leukemia-market

Treatment Insights

Treatments has divided chronic lymphocytic leukemia treatment market data into Chemotherapy, Targeted Drug Therapy, Immunotherapy, and Bone Marrow Transplantation. Chemotherapy segment dominated the market in 2023 and is expected to be the fastest growing segment during the forecast period 2023-2030. Chemotherapy is the first-line treatment for patients with chronic lymphocytic leukemia. It works by destroying cancer cells or reducing their growth rate. Standard chemotherapies include Dacogen (RAD-24), Cytarabine (Ablation), Fludara, fluorouracil, hydroxyurea, and procarbazine. Additionally, stem cell transplants can be used with chemotherapy, allowing healthcare providers to induce high-dose chemotherapy transfusions for effective treatment. Several companies are focusing on developing breakthrough drugs for the treatment of chronic lymphocytic leukemia in order to maintain their competitive edge and enter new regional markets. As a result, chemotherapy is the primary mode of treatment for most leukemia patients, thereby driving the growth of the segment market.

Furthermore, throughout the projection period, targeted medication therapy is the fastest-growing category in the chronic lymphocytic leukaemia treatment business. This therapy provides benefits over chemotherapy in terms of accuracy, therapeutic efficiency, and recovery time. Furthermore, targeted pharmacological treatments are becoming more common for treating this kind of chronic lymphocytic leukaemia.

Click here for request free sample report:

https://www.pharmanucleus.com/request-sample/1198

End User Insights

Based on end user, the chronic lymphocytic leukaemia therapy market has been segmented into hospitals and specialty clinics. Hospitals had the biggest sector share in 2023. Many hospitals worldwide are using cutting-edge treatments and equipment to treat chronic lymphocytic leukaemia. Stem cell transplantation is the principal therapeutic strategy for rare cases of leukaemia that occur only in hospital settings across the world. According to an article released by Apollo Hospitals, around 1 million cases of chronic lymphocytic leukaemia are diagnosed in India each year. According to cancer statistics, 1 in 155 men and 1 in 260 women in England will develop chronic lymphocytic leukaemia over their lifetime. A spike in the number of cancer patients is propelling the industry forward.

[pharmanucleus1]

Chronic Bronchitis Market: Advancements in Respiratory Care

Chronic Bronchitis Market Analysis and Size

The global chronic bronchitis market is expected to grow considerably over the projected period. The global increase in allergic reactions, as well as the growth of emerging markets, are moving this industry ahead. The increased prevalence of asthma and COPD, both of which cause severe coughing, is driving the chronic bronchitis market. The market is growing and is expected to grow fast throughout the projected period.

Click here for full report:

Pharmanucleus investigates the growth rate of the global chronic bronchitis market from 2023 to 2030. During the projected period, the worldwide chronic bronchitis market is estimated to grow at a CAGR of more than 4.0%. The Pharmanucleus team performed a thorough market analysis that included expert research, patient epidemiology, pipeline analysis, price analysis, and regulatory framework, as well as market data such as market size, growth rate, market segmentation, geographical coverage, market participants, and market situation.

Market Definition

Chronic bronchitis is an inflammatory disease that produces swelling and pain in the airways over time. The symptoms appear gradually and build to severe, maybe irreversible lung damage. A three-month cough happens every two years. The most common causes of chronic bronchitis include smoking and certain kinds of chronic obstructive pulmonary disease (COPD).

Global Acute Bronchitis Market Dynamics

Drivers

Increasing Prevalence of COPD

The rising incidence of COPD is a significant factor driving market expansion. According to a WHO report from June 2021, chronic obstructive pulmonary disease (COPD) is the third greatest cause of mortality globally, accounting for 3.23 million deaths in 2019. As a result, the rising prevalence of COPD is boosting need for chronic bronchitis therapy.

Growing Demand for Combination Therapy

Combination treatment is becoming increasingly popular since it is more effective than taking a bronchodilator and a corticosteroid individually. The growing number of patients effectively treated with combination therapy who did not respond to bronchodilators or corticosteroids is predicted to fuel the worldwide chronic obstructive pulmonary disease treatment market.

Click here for full report:

Opportunities

Rising Prevalence of Smoking

Smoking is one of the leading causes of death in the United States, resulting in more than 480,000 deaths each year. Smoking was highest among people aged 25-44 and 45-64. Thus, in turn, this leads to chronic bronchitis and creates opportunities for market growth.

Advanced Clinical Research and Innovative Strategies

Many industry participants are eager to put in place strategic measures that will help the sector thrive. The US Food and Drug Administration authorised Brovana in February 2022 for the treatment of bronchoconstriction in persons with chronic obstructive pulmonary disease (COPD). Brovana contains a bronchodilator, which is a medication that relaxes and widens the airways, hence relieving bronchoconstriction.

Restraints/Challenges

Lack of Awareness

Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global acute bronchitis market over a forecast period.

High Cost

The huge expenditure required for chronic bronchitis treatment is surely hampering the growth of the market.

This Global Chronic Bronchitis Market report provides details about recent new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share , the impact of national and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic analysis of market growth, market size, category market growth, niches and application dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To obtain more insights on the Global Chronic Bronchitis Market, contact Pharmanucleus for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Click here for request free sample report:

Chronic Bronchitis Market Scope

The global chronic bronchitis market is classified into four segments: treatment type, drug class, administration technique, end user, and distribution channel. Growth in these sectors will help you analyse weak growth areas in industries and provide users with important market knowledge and industry insights to help them make strategic decisions to uncover major market applications.

Treatment Type

Pharmacological

Nonpharmacological

Others

Drug Class

Bronchodilators

Glucocorticoids

Antibiotic

Phosphodiesterase-4 Inhibitors

Others

Route of Administration

Oral

Parenteral Inhalational

Others

End-Users

Hospitals

Specialty Clinics

Others

Distribution Channel

Hospitals

Specialty Clinics

Others

Regional Analysis/Insights

The global chronic bronchitis market is analyzed and market size insights and trends are provided by treatment type, drug class, route of administration, end user, and distribution channel as listed above.

The major countries covered in the global Chronic Bronchitis market report are USA, Canada & Mexico North America, Germany, France, UK, Netherlands, Switzerland , Belgium, Russia, Italy, Spain, Turkey, the rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia Pacific (APAC) within Asia Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) within Middle -East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

North America holds the largest market share owing to increasing infections in the geriatric population and growing smoking population.

Because of the rising incidence of COPD, asthma, and other lung disorders, as well as enhanced government and pharmaceutical organisation efforts to raise awareness, Asia-Pacific is likely to account for the greatest market share in the Chronic Bronchitis market in the next years.

The nation portion of the research also includes individual market affecting elements and changes in legislation in the market that affect present and future market trends. Additionally, the presence and availability of global brands, as well as the issues they face owing to big or scarce competition from local and domestic brands, are taken into account when giving forecast analysis of nation data.

[pharmanucleus1]

Revolutionizing Bladder Cancer Care: Market Insights

Bladder Cancer Market Overview

Bladder Cancer Market Size was valued at USD 5.5 Billion in 2022. The Bladder Cancer market industry is projected to grow from USD 5.8 Billion in 2023 to USD 8.2 Billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.60% during the forecast period (2023 - 2030). The rising cost of healthcare, rising burden of bladder disorders, and rising public awareness of bladder diseases and treatment options, are the key market drivers enhancing the market growth.

Click here for full report:

https://www.pharmanucleus.com/reports/bladder-cancer-market

Bladder Cancer Market Trends

The growing awareness of bladder disorders and accessible therapeutics is propelling market expansion.

Due to rising healthcare costs, rising healthcare expenditures, and increasing incidence of bladder cancer, the market for bladder cancer treatments and diagnostics may experience substantial expansion. For example, the World Coalition of Bladder Cancer Patients has declared March 2022 to be "Don't Go Red" Month for Bladder Cancer Awareness in an effort to increase public knowledge of the signs. harbingers and symptoms of the disease. Early detection is essential to improve long-term survival and quality of life. During the forecast period, these activities are expected to drive the growth of the market. Moreover, the rise of the market over the projected period is supported by the rising prevalence of bladder cancer globally. For example, according to statistics from the World Cancer Watch 2020, prostate and bladder cancers are two of the ten cancers with the highest incidence rates in the world. According to the same source, there will likely be 573,278 new cases of bladder cancer and 1,414,259 new cases of prostate cancer in both genders in 2020. Global cancer incidence drives the market over time .

Product launches and mergers and acquisitions by significant industry competitors are also expected to drive the market. Merck, known as MSD outside the US and Canada, announced an August 2021 label update for KEYTRUDA, an anti-PD-1 medication, for urothelial cancer.

Bladder cancer is the world's tenth most common cancer. The American Cancer Society predicts that around 83,730 Americans will be diagnosed with bladder cancer in 2021. Furthermore, $1.18 million in philanthropic contributions and institutional investments were utilised to construct bladder cancer research facilities at Birmingham University in the United Kingdom. Another trend supporting market expansion during the forecast period is an ageing population, which is more prone to bladder cancer. The elderly are more vulnerable to urinary tract cancer because their immune cells that fight malignant bladder tissue are diminished. According to the American Society of Clinical Oncology (ASCO), 90% of bladder cancer patients were over the age of 55 in January 2021.  Both smoking and occupational exposure, according to the American Cancer Society, can contribute to the development of bladder cancer. As a result, the Bladder Cancer market is growing.

Bladder Cancer Market Segment Insights:

Bladder Cancer Type Insights

Transitional cell carcinoma, invasive bladder cancer, superficial bladder cancer, adenocarcinoma, and other uncommon forms are included in the Bladder Cancer Market segmentation. In 2022, the transitional cell carcinoma segment dominated the global market. As a result, both affluent and poor countries' healthcare infrastructures have improved. The worldwide bladder cancer treatments market is expected to develop rapidly in the superficial bladder cancer category during the projected period. The growth of this sector is attributable to increased awareness of superficial bladder disease, improved healthcare infrastructure in both developed and developing countries, and technological improvements.

Click here for full report:

https://www.pharmanucleus.com/reports/bladder-cancer-market

Bladder Cancer Treatment Insights

The Bladder Cancer Market is divided into therapeutic categories, which include chemotherapy, radiation therapy, immunotherapy, radical cystectomy, and others. In 2022, the chemotherapy category will dominate the global market. This is due to the fact that a variety of chemotherapeutic therapies will be available in 2021. Immunotherapy, on the other hand, is predicted to have rapid growth in the bladder cancer therapy market. The increasing prevalence of the targeted conditions, the growing preference for immunotherapy over conventional therapies, and the expanding demand for monoclonal antibodies and biosimilars are the primary drivers of immunotherapy segment growth.

Bladder Cancer Diagnosis Insights

Based on diagnosis, the Bladder Cancer Market segmentation covers urine lab tests, cystoscopy, biopsy, imaging tests, and others. In 2022, the Cystoscopy segment led the Bladder Cancer Market. During a cystoscopy, the bladder and urethra's interior are examined using a telescope. A cystoscope is a specialist endoscope that is delivered via the urethra into the bladder to perform a direct visual inspection of the urothelium. Cystoscopy is inexpensive. The increased prevalence of bladder cancer, as well as product launches by leading market players, all contribute to the expansion of this market segment.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1196

Bladder Cancer End User Insights

End-user segmentation in the Bladder Cancer Market comprises hospitals, clinics, cancer care centres, and others. In 2022, the hospital sector dominated the Bladder Cancer Market. This is due to the rising use of technologically advanced treatment choices in hospitals throughout the world.

Bladder Cancer Regional Insights

By region, the study provides market insights across North America, Europe, Asia-Pacific, and Rest of the World. The bladder cancer market in North America led this market in 2022 (45.80%). This is a result of the region's expanding R&D activities and well-established healthcare infrastructure. The existence of numerous biologics and biopharmaceutical companies is another factor that has contributed to the size and skyrocketing growth of the bladder cancer therapeutics and diagnostics market. In the United States, there are approximately 81,180 new cases of bladder cancer in 2022 (61,700 in men and 19,480 in women), according to January 2022 statistics from the American Cancer Society. Hence, the need for bladder cancer detection and treatment is expected to increase as its prevalence rises, supporting the expansion of the market. Additionally, the US bladder cancer market held the largest market share, and the Canadian bladder cancer market was the fastest growing market in North America.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

The European bladder cancer market accounted for the healthy market share in 2022. This is due to the significant increase in bladder cancer cases in the European region. Bladder cancer is ranked as the 11th most dangerous disease in the UK with around 10,300 cases reported in the country between 2016 and 2018. Additionally, the German bladder cancer market held the largest share market share, and the UK bladder cancer market was the fastest growing market in the European region

The bladder cancer market in Asia Pacific is expected to register significant growth from 2023 to 2030. This growth is mainly attributed to increased awareness of bladder diseases and new diagnostic and therapeutic approaches. Major market players are investing heavily in Asia as they believe it is a lucrative market for bladder cancer and hence the market is growing there. With each passing year, the number of bladder cancer diagnoses is increasing significantly in the Asia-Pacific region. In 2018, there were 10,231 deaths and 18,921 cases of bladder cancer in India. Additionally, the Chinese bladder cancer market held the largest market share and the Indian bladder cancer market was the fastest growing market in the Asia-Pacific region.

Bladder Cancer Key Market Players & Competitive Insights

The major market players are investing heavily in research and development to expand their type ranges which will help the bladder cancer market grow even further. Market players are also undertaking various strategic activities to expand their global footprint, with significant developments in the market including new type launches, contractual agreements, mergers and acquisitions, larger investments, and collaboration with others organizations. To grow and survive in a more competitive and rising market climate, the bladder cancer industry must offer cost-effective items.

Local manufacturing to minimize operational cost is one of the major business tactics used by manufacturers in the global Bladder Cancer industry to benefit the customers and increase the market sector. In recent years, the bladder cancer industry has provided some of the greatest benefits to medicine. Major Bladder Cancer Market Players include AstraZeneca Plc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Novartis International AG, Pfizer Inc., Sanofi S.A. , Merck & Co. Inc., Accord Healthcare and Bedford Lab are trying to increase market demand by investing in type research and development.

Pharmaceuticals of all kinds are discovered, developed, produced and sold by Astellas Pharma Inc (Astellas). Marketed therapies for the treatment of various urological disorders, infectious diseases, cancer, nephrology and metabolic diseases, immunodeficiency diseases and transplantation are included in the Company's product portfolio. Its pipeline includes drug candidates for the treatment of various diseases, including acute myeloid leukemia (AML), urothelial cancer, gastric cancer, gastroesophageal junction cancer, anemia related to chronic renal failure (CRI) in dialysis patients, rheumatoid arthritis and non-dialysis patients. the patients. With the help of a network of subsidiaries and affiliates, it operates in America, Australia, Europe, Asia and Oceania. Tokyo, Japan is the headquarters of Astellas. Preliminary results from Cohort H of the EV-103 study, which is investigating PADCEV (enfortumabvedotin-jeff) as monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are not eligible cisplatin therapy, were published in February 2022 by Astellas Pharma Inc. and Seagen Inc.

A biopharmaceutical company called Merck & Co Inc (Merck) is engaged in the discovery, development, production and marketing of prescription drugs, biological therapies, vaccines and animal health products. It provides prescription products for the treatment of diseases such as diabetes, cancer, immunological diseases, cardiovascular diseases and cancer. Keytruda (pembrolizumab), which is used to treat urothelial carcinoma, received U.S. Food and Drug Administration approval in August 2021, according to Merck, a leading global biopharmaceutical company.

[pharmanucleus1]

Autoimmune Hepatitis Market: Transformative Treatments Await

Global Autoimmune Hepatitis Market, By Type (Type 1, Type 2), Treatment (Medications, Liver Transplant, Others), Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030

Market Overview

In recent years, the autoimmune hepatitis market is anticipated to grow rapidly during the forecast period. According to the 2019 study "Burden of Liver Diseases in the World," liver illness causes roughly 2 million fatalities worldwide, with 1 million deaths due to cirrhosis complications and 1 million deaths due to viral hepatitis and hepatocellular cancer. Cirrhosis is the 11th most prevalent cause of mortality globally, while liver cancer is the 16th most common cause of death. They are responsible for 3.5 percent of all deaths worldwide.

According to Pharmanucleus, the autoimmune hepatitis market was valued at USD 156.76 million in 2021 and is predicted to reach USD 210.61 million by 2030, showing a CAGR of 3.70% from 2023 to 2030. The Pharmanucleus team curated the market study, which contains extensive expert analysis, patient epidemiology, pipeline analysis, price analysis, and regulatory framework.

Please click here:

Market Definition

Autoimmune hepatitis is an uncommon but fatal liver disease. When the body mistakes healthy tissue and cells for infectious tissue and cells, antibodies are created to target the healthy liver cells. Autoimmune hepatitis can develop quickly or gradually. The condition's aetiology is unknown, however it may be related to other systemic disorders or medication exposure in some situations. Autoimmune Hepatitis Market Dynamics

Drivers

Increased incidence of autoimmune hepatitis

The rising prevalence of autoimmune hepatitis is a major contributor to the market's rapid expansion. Complications of such illnesses include swollen veins in the oesophagus, fluid accumulation in the abdomen, liver failure, and liver cancer.

Increasing healthcare infrastructure investment

Growing healthcare spending, which aids in infrastructure improvement, is another important aspect driving the autoimmune hepatitis market's growth rate.

The greater governmental and private-sector efforts to promote awareness of the would boost the autoimmune hepatitis market. Furthermore, people's changing lifestyles and high disposable income will drive the autoimmune hepatitis market upward. Furthermore, the expanding older population and an increase in medical tourism will accelerate the market's development pace.

Opportunities

Increase in the number of R&D activities      

Moreover, when R&D activity increases, so does the market. This will create new prospects for the autoimmune hepatitis industry to expand. Additionally, higher medication approvals and launches will drive market growth.

Furthermore, rising investments in the development of innovative technologies, as well as an increase in the number of emerging markets, will create further chances for the autoimmune hepatitis market to expand throughout the projected period..

Restraints/Challenges

On the other hand, the high cost of treatment will hamper the growth rate of the market. Lack of healthcare infrastructure in developing economies and low awareness of autoimmune hepatitis will pose major challenges to the market growth rate. Additionally, shortage of skilled professionals and missed diagnoses will further limit and hamper the growth rate of the market over the forecast period 2023-2030.

This report on the Autoimmune Hepatitis Market discusses recent new developments, trade regulations, import-export analysis, production analysis, value chain optimisation, share market analysis, the impact of national and localised market players, analyses opportunities in terms of emerging revenue pockets, market changes regulations, strategic analysis of market growth, market size, category market growth, niches and dominance of applications, product approvals, and p Contact Pharmanucleus for an Analyst Brief for more information on the Autoimmune Hepatitis industry; our experts will assist you in making an informed market choice to achieve market growth.

Please click here for full report:

https://www.pharmanucleus.com/reports/autoimmune-hepatitis-market

Patient Epidemiology Analysis

Autoimmune hepatitis is an uncommon condition that affects four times as many women as males. Type 1 diabetes is the most common and affects most individuals. Type 2 diabetes is more frequent in young individuals and progresses faster. Every year, 1 to 2 new cases per 100,000 people are expected, for a total of around 24 cases per 100,000 people.

Furthermore, the Autoimmune Hepatitis Market offers in-depth market data for patient analysis, prognosis, and therapy. Prevalence, incidence, mortality, and adherence rates are among the statistical aspects evaluated in the study. Analyses of the direct or indirect influence of epidemiology on market growth are performed in order to develop a more robust cohort multivariate statistical model to forecast market growth during the boom era.

Click here for Request free sample:

Post COVID Impact

Since its emergence in December 2019, the COVID-19 virus has indeed had a profound impact on healthcare systems worldwide, which has affected various medical conditions, including autoimmune hepatitis. The declaration of the virus as a public health emergency by the World Health Organization (WHO) prompted healthcare systems to prioritize COVID-19-related treatments and control measures. As a result, specialist healthcare services for other conditions, including autoimmune hepatitis, have faced delays and disruptions.

The financial crisis caused by the pandemic has further compounded the challenges in healthcare systems, leading to resource constraints and reduced access to medical services. Patients with autoimmune hepatitis have faced difficulties in seeing their healthcare providers for various reasons. Some individuals have struggled to access doctors due to overwhelmed healthcare facilities or limited availability of appointments. Fear of contracting the virus has also deterred patients from seeking in-person consultations. Moreover, pandemic-related restrictions, such as lockdowns and travel limitations, have hindered the continuity of essential therapies and procedures for autoimmune hepatitis patients.

These circumstances have the potential to negatively impact the autoimmune hepatitis market in recent months. Reduced access to care, delayed diagnoses, and interruptions in treatment may result in suboptimal disease management, increased disease progression, and worsened patient outcomes. Additionally, the economic consequences of the pandemic may limit patients' ability to afford necessary medications and therapies, affecting market demand.

However, as the global healthcare system adapts and recovers from the pandemic, efforts are being made to address these challenges. Telemedicine and remote healthcare services have gained prominence, allowing patients to connect with their healthcare providers virtually. Gradual easing of pandemic restrictions and resumption of regular healthcare services are expected to alleviate some of the barriers faced by autoimmune hepatitis patients, helping to stabilize the market over time.

Global Autoimmune Hepatitis Market Scope

The market for autoimmune hepatitis is classified by type, therapy, diagnosis, method of administration, end-users, and distribution channel. The growth in these segments will assist you in analysing the growth sectors in industries and providing users with a beneficial market overview and industry insights to assist them in making strategic decisions for finding key market applications.

[pharmanucleus1]

Asthma Treatment Market: Innovations for Breathing Relief

Asthma Treatment Market

Asthma Treatment Market is segmented By Treatment (Long-Term Control Medications,Quick-Relief Medications,Route Of Administration (Injectable,Oral,Inhaled), By Distribution Channel (Hospital Pharmacies,Retail Pharmacies & Drug Stores,Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) – Share, Size, Outlook, And Opportunity Analysis, 2023-2030.

Click here for full report:

https://www.pharmanucleus.com/reports/asthma-treatment-market

KEY MARKET INSIGHTS

The global asthma treatment market size stood at USD 18.08 billion in 2019 and is projected to reach USD 26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period.

In today's healthcare environment, respiratory health is critical, particularly because respiratory disorders such as asthma are among the major causes of mortality and disability globally. According to the World Health Organisation (WHO) study on "The Global Impact of Respiratory Disease" issued in 2017, an estimated 334 million people suffer with asthma. Individuals with moderate to severe asthma were at a higher risk of contracting acute respiratory illness during the 2019-2020 coronavirus pandemic, according to the Centres for illness Control and Prevention (CDC). Numerous clinical studies are being done by industry participants to explore novel asthma medicines, particularly in light of the 2019-2020 coronavirus pandemic.

MARKET TRENDS

Increasing R&D for Advanced Asthma Therapeutics to Augment Market Growth

One of the significant industry trends in this market is the strong and vigorous R&D being conducted by leading market players for the development of enhanced asthma treatments. Because asthma is a chronic condition that affects a large number of people globally, including children, a number of major pharmaceutical firms are active in the development of asthma medications. This engagement involves the availability of multiple promising asthma therapy candidates in various phases of clinical studies. For example, Novartis revealed good findings from the phase III IRIDIUM trial of the inhaled combination QVM149 in patients with uncontrolled asthma in September 2019. This asthma therapy medication candidate allows patients to better regulate their asthma symptoms, resulting in a significant improvement in the patients' health.

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1194

MARKET DRIVERS

Increasing Prevalence of Asthma Worldwide is Anticipated to Fuel Demand for Better Asthma Treatment Outcomes

One of the critical market drivers of this market is the increasing prevalence of chronic respiratory diseases such as asthma globally. Asthma is considered to be the most common chronic disease worldwide, and this has particularly driven the need for advanced therapeutics for asthma treatment. Asthma, if especially present in the individual in the severe form, is a severely debilitating disease and thus requires the administration of treatment drugs for asthma. Thus, the increasing need for a better quality of life for the patients undergoing asthma treatment is also expected to drive the market growth. According to the American Academy of Allergy, Asthma & Immunology (AAAAI), in the United States in 2016, it was estimated that approximately 8.3% of children in the U.S. had asthma. The introduction of low cost and effective therapeutics is anticipated to drive the growth of the global market during the forecast period.

Another major factor is the growing need for improved clinical and therapeutic asthma treatments in light of the 2019-2020 coronavirus pandemic. Asthma therapy is in high demand since both the COVID-19 and asthma are respiratory ailments. This is partly because, because asthma is the most prevalent chronic condition, with a big patient population pool, the COVID-19 is expected to aggravate asthma symptoms in those who suffer from it, prompting the need for effective asthma therapy. The Centers for Disease Control and Prevention (CDC), during the 2019-2020 coronavirus pandemic has issued special guidelines for patients undergoing treatment for asthma and also advocated greater precaution for asthma patients. This is projected to spur the demand for advanced asthma treatment drugs which, in turn, will favor growth of this market.

Click here for full report:

https://www.pharmanucleus.com/reports/asthma-treatment-market

Increasing Number of Product Launches to Drive the Asthma Treatment Market Growth

In light of the 2019-2020 coronavirus pandemic, there is a greater demand for various types of treatment drugs for asthma, because both the respiratory illnesses are closely linked. The increasing demand for asthma treatment has led to the U.S. FDA issuing priority regulatory approvals to a number of asthma drugs, which includes key generic equivalents. For instance, in April 2020, the U.S. FDA provided regulatory approval to Cipla’s key generic asthma treatment drug, and a similar generic equivalent from Lupin is also anticipated to gain regulatory approvals. Such developments and trends are further leading to the increasing product launches of significant capability from prominent companies. The increasing product launches are further undertaken in order to ensure that there are no significant asthma medications shortages. The above factors combined with the need for efficient therapeutics is further projected to fuel the demand for these drugs and boost the global market growth. 

MARKET RESTRAINT

High Cost of Asthma Medications Coupled with Underdiagnosis of Asthma to Restrain Market Growth

Despite the rising incidence of asthma worldwide, particularly in both emerging markets such as Asia and developed markets such as North America, several impediments to the adoption of these therapies exist. Higher prices associated with asthma inhalers, which are frequently regarded the primary therapy for Asthma, are one of the major reasons constraining market development. For example, the price of Advair, a vital asthma medicine, has grown from US$ 316 in 2013 to US$ 496 in 2018, a 56.0% increase. Aside from high drug prices, another significant element has inhibited market growth: asthma underdiagnosis.

Underdiagnosis of asthma results in inferior clinical outcomes for patients who are unable to use the right asthma medicines as a treatment for their medical condition. Such obstacles are expected to considerably stifle market expansion.

SEGMENTATION

By Treatment Analysis

Long-Term Control Medications Dominated the Global Market

The global market is divided into two categories based on treatment: long-term control drugs and quick-relief treatments. Because asthma is considered a chronic condition, the primary therapy for such problems is frequently long-term drugs for asthma control and management. As a result, long-term control drugs dominated the global market in 2019. Some of the important pharmaceuticals in this area include Advair, Qvar, and Symbicort, which have contributed to the segment's supremacy in the worldwide market. Inhaled and combination corticosteroids, leukotriene modifiers, anticholinergics, and immunomodulators are some of the important medication classes in this category.

The category of quick-relief drugs is expected to be the second-largest. This section's pharmacological classes include short-acting beta-agonists (SABAs), and the drugs in this segment give immediate relief of asthma symptoms by relaxing airway muscles. Albuterol sulphate is one of the most important asthma treatments in this sector.

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1194

By Route of Administration Analysis

Large Number of Products Administered Through Inhalation Anticipated to Aid in the Dominance of the Segment

The market is divided into injectable, oral, and inhalation routes of delivery. Because a considerable number of asthma medicines are provided in this manner, the inhalation sector is expected to dominate the method of administration segment. Some of the major products are Pulmicort and Qvar, and this sector is expected to maintain control of its market share over the projected period, resulting in the segment's dominance in the worldwide market. The injectable sector is expected to expand during the forecast period because a number of immunomodulators, an important medication class, are expected to rise during the forecast period and are injected subcutaneously.

The oral section is expected to increase slowly throughout the projection period. The rising influx of generic counterparts, as well as the increased absorption of immunomodulators, are likely to constrain sector growth throughout the projection period.

By Distribution Channel Analysis

Higher Administration of Therapeutics at Hospital Pharmacies to Enable Dominance of the Segment

The market is divided into three distribution channels: hospital pharmacies, retail pharmacies & pharmacy shops, and internet pharmacies. One of the primary reasons for hospital pharmacies' dominance is that the medicines used in asthma therapy are typically only available in hospital settings with educated medical experts. This allows for adequate adherence to treatment standards as well as the appropriate and safe delivery of important medications, some of which need subcutaneous injections. Asthma symptoms can frequently be effectively controlled with correct and suitable medication.

Retail pharmacies and drug stores are expected to command the second largest market share, owing to the refilling of asthma prescriptions such as inhaled corticosteroids, which can be done at these locations, being one of the major factors driving this segment's growth during the forecast period.

Because of the simplicity and convenience provided to patients in terms of purchasing crucial asthma drugs, internet pharmacies are expected to develop at the fastest CAGR.

[pharmanucleus1]

Antimicrobial Susceptibility Market: Precision in Pathogen Control

Antimicrobial Susceptibility Testing Market

The worldwide antimicrobial susceptibility testing market is expected to increase at a 5.5% CAGR from 2022 to 2027, from an anticipated value of US$3.6 billion in 2022 to US$4.7 billion in 2027. The Antimicrobial Susceptibility Testing (AST) Technology Market is expanding due to factors such as rising infectious illness prevalence, increased antibiotic resistance, and favourable government measures to minimise infectious disease burden. Antibiotic susceptibility testing is becoming more popular due to the rising prevalence of certain illnesses, such as bloodstream infections and pneumonia caused by E. coli, K. pneumonia, and P. aeruginosa, among others.

Click here for full report:

https://www.pharmanucleus.com/reports/antimicrobial-susceptibility-market

Antimicrobial Susceptibility Testing Market Dynamics

Drivers: Emergence of multidrug resistance due to drug abuse

The rise of drug resistance poses a significant threat to global health, particularly in the context of antibiotics. Antibiotics are becoming less effective as drug-resistant strains of bacteria spread worldwide. This has profound implications for disease treatment, as it makes infections more difficult to treat and ultimately increases mortality rates.

The World Health Organization (WHO) has identified drug-resistant pathogens, such as carbapenem-resistant gram-negative bacteria, as a major concern. Urgent development of new drugs is necessary to combat these infections effectively. However, without a fundamental change in the way antibiotics are used, the effectiveness of these new treatments may be compromised.

Misuse and overuse of antibiotics contribute to the development of drug resistance. Factors such as inappropriate prescribing, improper self-medication, and the use of antibiotics in livestock and agriculture all contribute to the problem. These practices create an environment where bacteria can adapt and develop resistance mechanisms, rendering antibiotics less effective over time.

To preserve the efficacy of antibiotics, it is crucial to promote responsible antibiotic use. This includes raising awareness among healthcare providers and the general public about appropriate antibiotic prescribing and the importance of completing prescribed courses of treatment. Additionally, robust regulations and surveillance systems are needed to monitor antibiotic use in various sectors, including healthcare, agriculture, and veterinary medicine.

Efforts to develop new antibiotics should be complemented by strategies to optimize their use, such as antibiotic stewardship programs and infection prevention and control measures. Research into alternative treatment options, such as phage therapy and immunotherapies, is also essential to diversify the arsenal against drug-resistant bacteria.

Opportunities: Growth opportunities in emerging market

The antimicrobial susceptibility testing market players are poised with significant opportunities in developing countries such as APAC (Asia-Pacific), India, China, and Japan. These countries are experiencing a notable growth in the antimicrobial susceptibility testing market, driven by several factors.

Firstly, the booming medical tourism industry in these regions attracts a large influx of patients seeking healthcare services, including diagnostics. This surge in medical tourism creates a demand for antimicrobial susceptibility testing as part of the diagnostic process.

Secondly, the adult population (over 20 years old) is growing in these countries, leading to a higher prevalence of infectious diseases. As a result, there is an increased need for accurate and timely antimicrobial susceptibility testing to guide appropriate treatment decisions.

Additionally, the increasing use of drugs in these regions contributes to the demand for antimicrobial susceptibility testing. With a growing population and expanding healthcare access, the requirement for testing to guide optimal drug selection and treatment outcomes becomes crucial.

Moreover, these countries possess a strong and skilled workforce that is well-versed in high technology. This skilled workforce plays a vital role in the successful implementation and operation of advanced antimicrobial susceptibility testing technologies, ensuring accurate and reliable results.

Furthermore, the relatively lax import/export laws in these regions provide an advantageous environment for market players to expand their brands and offerings. The underdeveloped nature of certain areas in these countries presents opportunities for companies to introduce and establish their technologies, filling gaps in the market and addressing unmet needs. 

The growing number of technicians and their desire to learn and adopt new technologies further contribute to the development and updating of antimicrobial susceptibility testing capabilities in these regions, fostering innovation and advancements in the field.

Click here for full report:

https://www.pharmanucleus.com/reports/antimicrobial-susceptibility-market

Challenges: Complex Regulatory Frameworks

One of the major challenges in antibiotic susceptibility testing is the time gap between establishing clinical thresholds, obtaining regulatory approval for innovative antimicrobial treatments, and bringing those drugs to market. The process of gaining approval for new drugs involves stringent guidelines set by regulatory bodies like the FDA, which can result in significant delays.

The lack of established clinical thresholds for certain drugs further complicates the use of products aimed at increasing the susceptibility of microorganisms. Clinical thresholds are important benchmarks used to determine the effectiveness and appropriate usage of antimicrobial therapies. In some cases, such as invasive mold infections other than Aspergillus, the efficacy of antifungal therapy cannot be accurately assessed without the availability of specific clinical thresholds.

This time lag and absence of clinical thresholds can hinder the timely utilization of innovative antimicrobial treatments. It delays access to potentially life-saving therapies and limits healthcare professionals' ability to make informed decisions regarding treatment choices. The gap between setting clinical thresholds, regulatory approval, and market availability needs to be addressed to ensure that effective antimicrobial treatments reach patients in a timely manner and contribute to the fight against drug-resistant microorganisms.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1193

Restraints: High Cost of automated Laboratory Instruments

Automated equipment for antimicrobial laboratories is quite expensive and offers premium features and functionality. The introduction of automated AST systems shortens incubation and detection times. Another barrier to this market is the high maintenance cost of  these devices, which come with the latest software and require regular maintenance.

[pharmanucleus1]

Airway Management Devices Market: Revolutionizing Patient Care

According to a recent study report, the airway management devices market is predicted to generate $1.8 billion in revenue in 2022, growing to $2.4 billion by 2028. This equates to a compound annual growth rate (CAGR) of 5.6% between 2022 and 2028. The research looks at market purchasing patterns, price analysis, patent valuation, conference and webinar materials, and industry trends. Several factors are propelling market growth, including a rise in surgical procedures, an increase in the prevalence of chronic respiratory illnesses such as asthma and COPD, and an increase in demand for airway management devices in emerging economies.

Click here for full report:

https://www.pharmanucleus.com/reports/airway-management-devices-market

Airway Management Devices Market Dynamic

DRIVER: Rising incidence of pre-term births globally

Preterm birth occurs when a baby is born before the full 37 weeks of pregnancy. Premature births have recently become more common on a global scale. Babies who have trouble breathing may benefit from mechanical ventilation. These infants may also have breathing difficulties, apnea, asthma, and other respiratory abnormalities. Taking these factors into consideration, the growing prevalence of pre-term neonates promotes demand for airway management equipment. Vendors are offering items that satisfy the needs of newborns and paediatric patients in order to address the need for products that come in a variety of sizes and forms for airway control.

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1192

Restraint: Lack of reimbursement policies across emerging countries

Pricey airway management devices are rarely frequently utilised in emerging nations due to poor reimbursement systems or a lack of public health insurance coverage. Individuals are pushed to spend money they don't have because of ineffective policies and a lack of support for universal health care, which has a negative impact on the financial status of the poor throughout developing countries. Such circumstances have made a country more vulnerable to the threat of chronic diseases. Due to the high out-of-pocket costs of healthcare, the restricted adoption of costly medical devices such as video laryngoscopes and advanced surgical methods in developing countries has become a key market constraint.

OPPORTUNITY: Rising growth potential in developing countries

Market participants may anticipate future development opportunities from growing economies such as China, India, and Brazil. The primary motivation for development is because China and India have massive target patient populations. China's one-child policy has resulted in a considerable decrease in working-age population while increasing the elderly population. Furthermore, Malaysia and India have become important medical tourism hubs. Surgical procedures in these impoverished countries are substantially less expensive than in wealthier countries like the United States, Germany, France, and the United Kingdom. As the number of procedures grows, more airway management and anaesthetic treatments will be necessary.

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1192

CHALLENGE: Dearth of skilled professionals

Advanced training is required for airway management procedures such as cricothyrotomy, tracheostomy, and endotracheal intubation. Due to a lack of knowledge regarding the optimal course of urgent treatment, the patient's health may deteriorate, the recovery period may prolong, and direct and indirect expenditures may rise. A scarcity of anesthesiologists and paramedics is a big concern for governments all over the world. The paucity of airway management equipment used in these surgeries has further impacted the efficacy and ability of healthcare facilities to provide surgical and emergency treatment.

Click here for full report:

https://www.pharmanucleus.com/reports/airway-management-devices-market

Airway Management Devices Ecosystem

The airway management devices market is dominated by players such Medtronic (Ireland), ICU Medical

[pharmanucleus1]

Acute Pancreatitis Market: Breakthrough Treatments, Insights

Market Overview:

The Acute Pancreatitis Market Size was valued at USD 5.5 billion in 2023 and is projected to grow from USD 5.8 Billion in 2023 to USD 8.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.90% during the forecast period (2023 - 2030). The major market driver fueling the expansion is the increased prevalence of gastrointestinal issues.

Click here for full report:

https://www.pharmanucleus.com/reports/acute-pancreatitis-market

Acute Pancreatitis Market Trends

Increase in the occurrence of acute pancreatitis to propel market growth

According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 275,000 Americans are hospitalized each year for acute pancreatitis (NIDDK). When the pancreas swells and becomes irritated, pancreatitis (swelling) results. It is not a widespread disease. The most common reasons are gallstones or excessive alcohol consumption. The disease can develop gradually over time or come on suddenly, causing serious injury. Treatment for pancreatitis may include intravenous (IV) fluids, painkillers, and other medications. Rising occurrence of acute pancreatitis globally will be a key factor in increasing the market growth rate. Gallstones and excessive alcohol consumption, especially in young people, are the main causes of acute pancreatitis. Gallstones are the most common cause of AP, accounting for 28-38% of cases, and alcohol consumption is the second most common cause, accounting for 19-41% of cases, according to an article published in the World Journal of Clinical Cases. - Assessment and management of acute pancreatitis in 2019. The likelihood of developing acute pancreatitis increases as the number of people with gallstones increases. Thus, this factor is driving the CAGR of the market.

Additionally, there is growing global interest in understanding the impact of chronic comorbidities on people with acute pancreatitis. Recent research published in BioMed Hub in November 2021 revealed a correlation between gastrointestinal symptoms in the early stages of acute pancreatitis and pre-existing conditions such as metabolic syndrome, obesity and diabetes mellitus. Another PLOS One article from June 2021 points out that obesity is an important public health problem in France, as it increases the likelihood of developing chronic diseases such as diabetes, hypertension and other conditions with psychological and serious social. The increasing prevalence of obesity and its association with excessive eating habits also increases the risk of pancreatitis, contributing to the growth of this market segment. As a result, the acute pancreatitis market is expected to grow steadily throughout the forecast period, driven by factors such as rising prevalence of obesity and growing use of intravenous therapy.

However, the sector will increase as the elderly population grows and government awareness efforts are implemented. Furthermore, changing consumer lifestyles and increasing government-welcoming policies will propel market growth. An growth in the number of R&D activities is another factor driving the market's expansion. As a consequence, this aspect is likely to increase acute pancreatitis market revenue globally.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1191

Acute Pancreatitis Market Segment Insights:

Acute Pancreatitis Cause Insights

Gallstones, alcohol, and other factors are among the causes of Acute Pancreatitis Market segmentation. According to Acute Pancreatitis Market statistics, the gallstones category held the most share in 2023. Acute pancreatitis is becoming more common over the world, as are gallstones. Gallstones cause around 40% of instances of acute pancreatitis. Gallstones afflict around 20 million people in the United States. Approximately 300,000 cholecystectomies are done on these individuals each year.

Acute Pancreatitis Treatment Insights

The therapy segmentation of the Acute Pancreatitis Market covers intravenous fluid, nutritional assistance, analgesics, endoscopic retrograde cholangiopancreatography (ERCP), and others. The intravenous fluid segment dominated market growth in 2023 and is expected to be the fastest-growing segment during the forecast period, 2023-2030, owing to factors such as the increased prevalence of acute pancreatitis, gallstones, and obesity in the population, as well as the risk factors associated with them. Acute pancreatitis is connected with dehydration and extreme fluid loss, which can be lethal and end in the patient's death. Intravenous fluid supply keeps the body hydrated, ensuring adequate blood flow to the other organs.

Acute Pancreatitis Diagnosis Insights

Based on diagnosis, the Acute Pancreatitis Market data covers imaging tests and laboratory testing. The laboratory testing category led the acute pancreatitis market revenue in 2023 and is expected to increase at the fastest rate during the forecast period, 2023-2030. Amylase and lipase are important pancreatic enzymes that may be detected through laboratory testing. The following may cause blood to gush. Other blood tests can be performed to detect gallbladder obstruction or injury.

Click here for full report:

https://www.pharmanucleus.com/reports/acute-pancreatitis-market

Acute Pancreatitis End-User Insights

End-users in the worldwide acute pancreatitis sector include hospitals, clinics, and others. Hospitals led the market in 2023 and are expected to be the fastest-growing sector throughout the forecast period, 2023-2030. The fact that hospitals are usually well-stocked and offer all services under one roof motivates patients with acute pancreatitis to seek treatment there. Another factor driving rising hospital visits is the increasing penetration of connected devices and equipment.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1191

Acute Pancreatitis Regional Insights

According to the research, the market is classified into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. The acute pancreatitis market in North America is expected to reach USD 2.5 billion in 2023, with a share of around 45.80%, and to grow at a rapid CAGR throughout the research period. Acute pancreatitis, obesity, and gallstones are all on the rise. These factors, together with a well-established healthcare infrastructure and high healthcare spending, are driving market expansion.

Significant countries included in the market study are the United States, Canada, Germany, France, the United Kingdom, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

The Asia Pacific acute pancreatitis market is the world's second biggest. The risk of pancreatic inflammation has increased as a result of growing obesity rates caused by changing lifestyles, which is projected to fuel market growth. Acute pancreatitis pharmaceutical and device-based therapies are expected to be in high demand, driving market development as R&D efforts in the area expand. Furthermore, the acute pancreatitis market in China was the largest, while the acute pancreatitis market in India was the fastest growing. Between 2023 and 2030, Europe's acute pancreatitis market is predicted to develop at the quickest CAGR. This is due to growing demand for certain drugs, and rising healthcare expenditures will accelerate market expansion in this area even more. The presence of significant competitors, as well as growing usage of newer technologies, will hasten market development in this business. Furthermore, the acute pancreatitis market in the United Kingdom was the largest, while the acute pancreatitis market in Germany was the fastest expanding.

[pharmanucleus1]

Acupuncture Needles Market: Innovations Driving Growth | Expert Insights

Market Overview

The acupuncture needle market is expected to earn $240 million in sales in 2022 and $308 million by 2030, rising at a compound annual growth rate (CAGR) of 5.1% from 2023 to 2030. The new study report is an assessment of the market's key trends. Market buying patterns, pricing analysis, patent analysis, conference and webinar materials, and industry trends are all part of the most recent research study. The growing frequency of musculoskeletal pain, the number of injuries and procedures, and these trends are the key drivers of market expansion.

Acupuncture Needles Market Dynamics

Driver: Increasing prevalence of back, muscle, and neck pain

The outcomes of the study point to acupuncture as a viable therapy for persistent low back pain. Acupuncture points, according to Western practitioners, are places for stimulating connective tissue, muscles, and nerves. This stimulation is thought to augment the body's natural painkillers. Back pain affects up to 80% of Americans at some time in their life, according to Practical Pain Management. The treatment of low back pain (LBP) costs the US healthcare system at least USD 50 billion a year. Musculoskeletal problems affect 1.71 million individuals globally, according to the WHO (July 2022).

Click here for full report:

https://www.pharmanucleus.com/reports/acupuncture-needles-market

Growing demand for acupuncture

Acupuncture is becoming more popular at wellness centres, spas, and even beauty clinics. This diversification has resulted in the development of specialised acupuncture needles to meet the specific treatment requirements of different contexts.

Furthermore, the rise of e-commerce platforms has made acupuncture needles more widely available. A large selection of acupuncture needle alternatives are now available on online markets, bringing convenience and choice to both practitioners and consumers.

Restraint: Alternative methods and medicines

Alternative forms of stimulation are frequently employed over the acupuncture sites in place of needles. Among others, they include electromagnetic energy impulses, friction, heat (moxibustion), pressure (acupressure), and suction (cupping). Non-steroidal anti-inflammatory medicines (NSAIDs) are among the most often prescribed medications and have a variety of applications in the treatment of back and muscular pain. One major problem impeding the market's expansion is the use of complementary therapies and pharmaceuticals (such NSAIDs) to treat headaches, tight muscles, arthritis, and other aches and pains.

Opportunity: Use of acupuncture in rehabilitation of COPD patients

The outcomes of the study point to acupuncture as a viable therapy for persistent low back pain. Acupuncture points, according to Western practitioners, are places for stimulating connective tissue, muscles, and nerves. This stimulation is thought to augment the body's natural painkillers. Back pain affects up to 80% of Americans at some time in their life, according to Practical Pain Management. The treatment of low back pain (LBP) costs the US healthcare system at least USD 50 billion a year. Musculoskeletal problems affect 1.71 million individuals globally, according to the WHO (July 2022).

Challenge: Issues related to acupuncture standardization

There are a number of controversies or even issues that are misunderstood in the acupuncture and moxibustion industry as a result of the special characteristics of acupuncture therapy based on syndrome distinction. The growth of standardisation in various domains is being slowed down by these issues. According to a poll, 36.1% of respondents said that standardising moxibustion and acupuncture would limit the features of treatments based on the differentiation of syndromes and personalised care.

Click here for full report:

https://www.pharmanucleus.com/reports/acupuncture-needles-market

Disposable segment accounted for the largest share of the acupuncture needles market, by type

The market is divided into disposable and non-disposable needles based on kind. The market has a bigger percentage of disposable needles. The danger of disease transmission will be reduced by the use of disposable needles.

The non-disposable needles category is expected to increase at a modest rate in the acupuncture needles market throughout the forecast period. One of the biggest disadvantages of this product's material rate is the significant danger of disease transmission from one patient to another via non-disposable needles. Non-disposable needles, on the other hand, are extensively utilised in undeveloped and underdeveloped nations due to a lack of basic awareness about hygiene and Hospital Acquired Infections (HAIs) among patients and healthcare personnel.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1190

Stainless-steel segment accounted for the largest share in the acupuncture needles market, by portability

The market is divided into stainless steel, gold, silver, plastic, and copper segments according on the handle material. Due to the lower price of stainless steel and the ease of availability, the stainless-steel handle needles category is expected to account for the greatest share over the projection period.

Clinics segment accounted for the largest share in the acupuncture needles market, by end user

Based on end users, the market is divided into hospitals and clinics. The clinical industry dominated the market. The rising number of private acupuncture clinics globally is the primary driver of this market segment's growth.

Online pharmacies segment accounted for the largest share in the acupuncture needles market, by distribution channel

The market has been divided into hospital, retail, and internet pharmacies based on the distribution route. The biggest market share, 49.0%, was held by the category of internet pharmacies. This is explained by elements like how simple it is to obtain a variety of goods in internet pharmacies.

Asia Pacific is the largest region for acupuncture needles market.

The global market is divided into four regions: North America, Europe, Asia Pacific and Rest of the World. Asia-Pacific held the largest market share, followed by Europe. The main driver of the market is the recent increase in the number of  local and international companies doing business in the Asia Pacific region.

Technology Trends

Acupuncture needle manufacturing has seen a spike in technological developments. Acupuncture needle manufacturers are actively investing in research and development to improve the design, materials, and manufacturing process. This has resulted in the development of needles with increased sharpness, reduced pain, and higher insertion efficiency.

Furthermore, the incorporation of nanotechnology has opened up new possibilities in the production of acupuncture needles. To improve the therapeutic effects of needle coatings, nanoparticles are being introduced. Such advancements are projected to transform the acupuncture needle industry, giving patients more effective and tailored treatment alternatives.

[pharmanucleus1]

Advanced Wound Care Market: Innovations Driving Healing Solutions

Advanced Wound Care Market Overview

The global advanced wound care market is estimated to be worth US$11.2 billion  in2023 and is expected to reach US$17.7 billion by 2030, growing at a CAGR of 9.4% over that period. Studying industry trends in the market is a new research report. The latest research  includes market buying patterns, pricing analysis, patent analysis, conference and webinar materials, and industry trends. Rising spending on chronic wounds, the prevalence of diseases and disorders that impede wound healing, and advances in technology are  key drivers of market growth.

Click here for full report:

Advanced Wound Care Market Dynamics

Driver: increasing number of surgical procedures across the globe

More operations are anticipated as surgical therapy becomes more available and cheap on a worldwide basis. Along with the development of chronic conditions and the expansion of surgical treatments, the frequency of associated surgical wounds and infections has grown. This will increase demand for better wound care products and debridement techniques in addition to cutting-edge therapies like NPWT.

Surgical procedures frequently cause tissue damage, extreme bleeding, or wound infections. Utilising cutting-edge wound care solutions, such as antibacterial honey wound dressings, has become a viable alternative to hasten the healing process by reducing wound bacterial colonisation and infection. More people are opting to employ sophisticated wound care treatments both before and after surgical operations as a result of a product's demonstrated advantages and the growing public awareness of their efficacy.

Click here for free sample request:

https://www.pharmanucleus.com/request-sample/1184

Restraint: High cost of advanced wound care products

The expensive cost of modern wound care products and chronic wound therapies may prevent their widespread use, particularly in low-income regions like Asia and the rest of the world. In these areas, patients and doctors choose affordable sophisticated wound care solutions. The preference for advanced wound care products is anticipated to rise over the next years, nevertheless, as more people become aware of the usefulness and necessity of these goods and as disposable incomes rise in many of these nations.

Opportunity: Growth potential of emerging economies

The markets for improved wound treatment in Asia Pacific and Latin America are less developed and offer greater market potential than those in Europe and North America. As a result, different players are concentrating on boosting their presence in certain areas. Major market participants have considerable development prospects in emerging economies including South Korea, Malaysia, Vietnam, South Korea, Africa, Israel, Saudi Arabia, and the United Arab Emirates. This may be as a result of relatively simple rules and restrictions, improvements in healthcare facilities including hospitals and clinics, an escalating patient population, particularly among the elderly, and rising healthcare costs.

Trend: Focus on expanding the current technologies and launching novel products.

The development of new products with absorbent, moisturizing and antibacterial properties is the result of research and development work to improve wound care products, including dressings. This in turn has led to a shift from simple to sophisticated dressings and an increased demand for products containing pharmacologically active ingredients. Market innovations are driven by the need to improve wound bed tissue condition and provide products that control wound healing.

Click here for full report:

The dressings segment accounted for the largest share of the advanced wound care market by product type.

The worldwide market is divided into topical agents, grafts and matrices, and dressings, devices, and accessories based on products. In 2023, the dressings sector held the biggest market share for advanced wound care, primarily as a result of growing patient education and an increase in HAI cases. This market is growing as a result of elements such the increasing incidence of venous ulcers, pressure ulcers, and diabetic ulcers.

The surgical and traumatic wounds segment accounted for the largest share of the advanced wound care market, by wound type.

The surgical and traumatic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, burns, and other wounds are the wound types into which the worldwide market is divided. Due to a rise in surgical operations done and an increase in the occurrence of SSIs, the surgical and traumatic wounds category will have the greatest share of the advanced wound care market in 2023.

Hospitals, ASCs, and wound care centers accounted for the largest share of the advanced wound care market by end user.

Hospitals, ASCs, and wound care facilities are one sector of the worldwide market, along with home care settings and other end users. The sector of hospitals, ASCs, and wound care facilities held the biggest market share for advanced wound care in 2023. The most significant market factors influencing the growth of this end-user category are the rise in hospital admissions for chronic wounds (such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers) and the incidence of pressure ulcers and infections acquired in hospitals.

North America is the largest region of the advanced wound care market.

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the five primary regions of the worldwide market. The biggest market share is held by North America. The increasing number of acquisitions made by well-known North American firms is contributing in the expansion of the worldwide market in this industry. Demographic trends, increased patient awareness, and high market penetration of advanced wound care products are expected to fuel market expansion.

Pipeline Analysis

The advance wound care product pipeline encompasses a range of cutting-edge technologies and therapies designed to address various aspects of wound healing. These advancements are driven by a growing understanding of the complex biological processes involved in wound repair and an increasing demand for more effective treatments.NPWT is a widely adopted technique that involves applying negative pressure to a wound to promote healing.Cellular therapies involve the use of living cells to stimulate tissue repair and regeneration. Stem cell-based therapies, in particular, have shown promise in promoting wound healing by enhancing the production of growth factors and facilitating the regeneration of damaged tissues. Organogenesis Inc. and Osiris Therapeutics are at the forefront of developing cellular therapies for advanced wound care.

Competitive Landscape

As competition intensifies, companies are striving to differentiate themselves through research and development efforts. The future of advance wound care holds great promise for patients and healthcare providers alike, with the potential to transform the way wounds are managed and healed. Key market participants include Smith & Nephew, Mölnlycke Health Care, Acelity, Organogenesis Inc., and Osiris Therapeutics. These companies are investing heavily in research and development activities to bring innovative products to market and gain a competitive edge.

[pharmanucleus1]

Global Osteoarthritis Market: Trends, Treatment, and Projections 2030

Report Summary 

In 2023, the worldwide osteoarthritis market was valued at USD 7.40 billion and is predicted to increase at an 8.5% CAGR during the forecast period 2023-2030. Both the introduction of analgesic drugs and the development of imaging diagnostics based on radiographic characteristics are stimulating market growth. Increased expenditure on healthcare infrastructure and expanding investments in research and development (R&D) efforts to bring novel diagnostics and biomarkers are also driving the market. 

Osteoarthritis (OA) is a group of disorders that affect the joints of the knees, hips, fingers, foot, back, shoulders, and neck. It is distinguished by the gradual degeneration of the cartilage in these joints. Stiffness, edoema, discomfort, persistent pain, loss of flexibility, a grating sensation, bone spurs, and sleep interruptions are all common symptoms of OA. 

Click here for full report:

Medical examination, X-rays, arthroscopy, joint fluid analysis, lab testing, and magnetic resonance imaging (MRI) scans can all be used to diagnose it. Depending on the outcomes, different medications and surgical techniques are prescribed to treat the disease's signs and symptoms. There are presently alternative medicines, physical therapy, and supporting devices on the market to relieve pain and improve joint function. 

Sedentary lifestyles, poor eating habits, and increasing weight and blood sugar levels make people more susceptible to develop OA. This is one of the primary driving drivers for market development, combined with an ageing population that is more susceptible to such disorders. Furthermore, the ease of access to MRI scans is a key growth-promoting factor. 

The COVID-19 outbreak is predicted to have only a minimal influence on the osteoarthritis therapy industry. Corticosteroids are being used less often in many medicine types. Although there is no evidence that corticosteroid injections significantly increase the risk of infection, the immune system may be less active for a few weeks following surgery. 

Even though the risk is extremely minimal, it should be taken into account before starting with the procedure. It should be noted that the World Health Organisation cautioned against the use of systemic corticosteroids in one of its guidelines for treating severe acute respiratory infections caused by coronavirus. 

Industry Dynamics 

Growth Drivers:  

Increased government investment on cell-based research, as well as the increasing use of opioids, are driving market expansion. Topical, oral, and analgesic medications are commonly used to treat osteoarthritis pain. Even if alternatives such as orthopaedic braces are used as part of a noninvasive approach to pain therapy, the adoption of pain pills for the disease is substantial due to the ease of administration and the cost of pain medications. Oral analgesics such as acetaminophen, NSAIDs, intra-articular medicines, and nutraceuticals are all common pain relievers. 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

The use of biomarkers to identify individuals who are most likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposing patients to medicines that are either unlikely to be effective or may cause harmful side effects from their treatment. Using a mix of unique biomarkers and baseline clinical parameters such as age and gender might be beneficial. 

Report Segmentation 

The market is primarily segmented based on treatment type, disease type, distribution channel, route of administration, and region. 

Click here for full report:

Knee Osteoarthritis segment is expected to witness fastest growth 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

Furthermore, increased FDA approvals for the treatment of Knee OA are driving sector growth throughout the projection period. For example, Novartis announced in September 2021 that LNA043 had been granted fast-track designation by the US Food and Drug Administration (FDA) for knee osteoarthritis rehabilitation. 

Drugs targeted to treat severe diseases and address unmet medical needs can be created more swiftly and evaluated more quickly. LNA043, a possibly first-in-class disease-modifying treatment for osteoarthritis, is being developed. As a result, growing approvals for the treatment of knee OA drive market development throughout the projection period. 

Click here for free sample request:

Viscosupplementation segment industry accounted for the highest market share in 2021 

The rising prevalence of knee osteoarthritis is the key driver of this market's expansion. By injecting synovial fluid into the afflicted joints, which increases lubrication, viscosupplementation greatly lowers osteoarthritis discomfort. Furthermore, the market for viscosupplementation agents is expected to grow considerably over the forecast period due to the discovery of novel viscosupplementation agents and government efforts to boost research in the healthcare sector. 

Hospital Pharmacies are expected to hold the significant revenue share 

Hospital pharmacies retained the largest share of this market due to the large number of patients seeking treatment for osteoarthritis in hospitals and the vast assortment of osteoarthritis drugs available in these pharmacies. Another important advantage is the ease with which hospital pharmacy purchases may be reimbursed. 

The demand in North America is expected to witness significant growth 

A rise in the frequency of chronic diseases, an increase in the number of elderly people, and changes in people's lifestyles all contribute to the anticipation of market expansion in North America. As a result, the region is incorporating an increasing number of treatments and drugs. When compared to Canada and Mexico, the United States will command a substantial share of the North American market for osteoarthritis therapies. 

According to the CDC, osteoarthritis (OA), the most common kind of arthritis, is a severe chronic illness that affects 32.5 million individuals in the United States. OA is associated with ageing and is more common in those with other chronic conditions such as obesity, diabetes, and heart disease. However, 18.7 million people with OA, or more than half of them, are of working age (18 to 64 years). 

Furthermore, the availability of better treatment alternatives, government reimbursement guidelines, increased research and development activities in the creation of novel medicines, and the introduction of new therapies in the North American region are all expected to support market expansion in the region. 

Europe controlled the market for osteoarthritis therapies. The increased incidence of osteoarthritis, the ageing population, rising obesity rates in several European countries, and the growing number of sports- and accident-related injuries all contribute to this sector's large market share. 

[pharmanucleus1]

Global Opioid Use Disorder Market: Navigating the Insights and Innovations

Opioid Use Disorder Market 

KEY MARKET INSIGHTS 

The global Opioid Use Disorder (OUD) Market size was valued at USD 2.88 billion in 2023 and is projected to grow from USD 3.11 billion in 2022 to USD 5.64 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period. Based on our analysis, the global market exhibited a decline of -10.1% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with opioid use disorder experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.

Click here for full report:

https://www.pharmanucleus.com/reports/opioid-use-disorder 

Opioid Use condition (OUD) is a complicated condition characterised by the compelling use of opioid medicines, even if the individual wishes to quit or if the drugs significantly impact the person's mental and physical well-being. Buprenorphine, methadone, and naltrexone are the three pharmacological groups used in the pharmaceutical therapy. These are the only drug classes authorised by the FDA in the United States. 

The number of prescriptions for painkillers, which commonly contain opioids, is expected to climb as the worldwide population of individuals suffering from chronic pain grows. When these opioid-based medications are used and the patient's suffering is relieved, the patient's reliance or addiction to these drugs rises. This addiction is dangerous since an opioid overdose can result in death or lifelong impairment of a person's normal psychological and physiological functioning. 

Several governments, like the United States, have put laws in place to successfully handle this condition in order to lessen the risk. These legislative reforms, together with the increasing number of product releases by big corporations, are expected to have a positive influence on the sector. 

Click here for sample request:

https://www.pharmanucleus.com/request-sample/1182

POST COVID-19 IMPACT 

Reduced Demand for Medications amid COVID-19 Pandemic to Negatively Impact Market Growth? 

Depending on the demand, the COVID-19 pandemic had both beneficial and bad effects on pharmaceutical firms. Certain pharmaceutical items saw a drop in demand as fewer individuals risked visiting healthcare institutions such as hospitals and clinics. To stop the spread of the coronavirus epidemic, the different governments ordered strict national lockdowns. As a consequence, patient visits to hospitals decreased dramatically. Non-essential medical services cancellation or delay impacted market development as well. 

On the other side, there was a noticeable increase in patients having opioid overdoses and relapses in the OUD market. However, well-known firms in the field, such as Indivior, saw a significant drop in product sales during this time. Sales continued to fall sharply as a result of Covid-19-related problems. As a result, the worldwide market saw a negative trend during the epidemic. 

Click here for full report:

https://www.pharmanucleus.com/reports/opioid-use-disorder

LATEST TRENDS 

Increasing Consideration of Buprenorphine Patches as an Effective Treatment Mode to Propel Market Growth 

The industry has lately seen an increase in the demand for buprenorphine treatment patches. These patches are regarded as an effective medication for the treatment of opioid use disorders. The numerous advantages associated with transdermal patches, such as ease of medication delivery and decreased discomfort, are customary and self-administered. Furthermore, these transdermal patches may be a viable option for individuals requiring round-the-clock opioid medication for opioid use disorder. 

In 2019, for example, WellSpan Health collaborated with York Opioid Collaborative to conduct a clinical study to develop a Lidocaine patch for the treatment of OUD. During the projected period, such collaboration is expected to boost treatment uptake. Furthermore, increased patient participation is expected to drive worldwide Opioid Use Disorder (OUD) market growth throughout the forecast period. 

DRIVING FACTORS 

Growing Opioid Addiction Cases to Augment the OUD Market Share? 

The worldwide population is today suffering from a variety of severe and chronic ailments, including pain, cancer, cardiovascular disease, and other problems. To treat these problems, painkillers, particularly opioids, are used. Drug usage frequently leads to drug addiction in the patient. The patient is expected to have drug withdrawal symptoms as a result of their increasing reliance on these drugs and their sudden discontinuation. 

According to the National Drug Dependence Treatment Centre's (NDDTC) Magnitude of Substance Use in India report published in February 2019, the prevalence of current opioid use is 2.06%, and approximately 0.55% of Indians are expected to require help for opioid use problems (harmful use and dependence). 

On account of these factors, the likelihood that patients will experience tragic outcomes, such as death induced by an opioid overdose, rises. 

Growing Focus of Government & Non-government Institutions to Support Expansion 

Another major driving reason driving market development is the growing involvement of governmental and non-governmental organisations in raising awareness about opioid overdose and associated consequences. The number of opioid addicts has substantially grown, prompting various organisations to take a more comprehensive strategy to combating the problem. Numerous countries have increased their efforts to support patients and reduce the effects of opioid addiction. 

For example, in March 2022, the Department of Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and prevent prescription drug misuse. 

Similarly, similar programmes are expected to encourage more people suffering from opioid addiction to seek treatment. These factors are expected to have a positive impact on the worldwide market throughout the forecast period. 

RESTRAINING FACTORS 

Adverse Effects of OUD Drugs to Restrain Market Growth? 

The adverse effects of the medications used to treat opioid addiction are expected to stymie the market throughout the projected period. 

These medicines commonly cause muscular pains, vomiting, diarrhoea, bone/joint pain, respiratory difficulties, bladder discomfort, constipation, and stomach cramps. Furthermore, in severe situations of adverse medication response, the patient may suffer from depression and other psychological issues. 

The hazards connected with these pharmaceuticals have resulted in a warning from the US Food and Drug Administration, which has a negative influence on the drug class, lowering the adoption of medications in this form of treatment. 

For instance, in January 2022, the U.S. FDA warned about dental problems with buprenorphine medicines dissolved in the mouth to treat OUD and pain. Dental issues, including oral infections, cavities, tooth decay, and teeth loss can be serious and have been reported even in patients with no history of dental issues. 

Such factors might hamper the market growth during the forecast period to a certain extent. 

[pharmanucleus1]

Global Neuropathic Pain Market : Unveiling Opportunities,Trends and Treatment Advancements.

Global Neuropathic Pain Market

Global Neuropathic Pain Market, By Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (Tens) Devices), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, Others), End User (Hospitals, Clinics, Home Healthcare,?Ambulatory Surgical Centers?and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel And Rest Of Middle East And Africa, Brazil, Argentina And Rest of South America) Industry Trends and Forecast to 2030 

Click here for full report:

https://www.pharmanucleus.com/reports/neuropathic-pain

 Market Analysis and Insights: Global Neuropathic Pain Market 

From 2023 to 2030, the worldwide neuropathic pain market is predicted to increase at a CAGR of 9.2%. The market is being pushed by the rising prevalence of chronic pain and neuropathic pain syndromes linked to a variety of illnesses. Neuropathic pain is caused by a somatosensory system lesion or illness and affects 7-10% of the general population. Multiple causes of neuropathic pain have been identified, and its prevalence is expected to rise due to an ageing global population, an increase in diabetes mellitus, and improved cancer survival following treatment. 

The industry is also being pushed by rising R&D expenditures by major market participants in order to develop better goods. However, the market is constrained by limits associated with medical equipment, which limit product application. Furthermore, the usage of traditional medicines in emerging nations due to poor health spending and a disrupted supply chain is projected to provide a hurdle to market expansion. 

The market for neuropathic pain is classified into three categories: kind, end-user, and geography. The market is separated into two segments: peripheral and central neuropathic pain. End-user categories in the market include hospitals, clinics, home healthcare, and ambulatory surgery centres. North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa make up the market. 

The North American market is expected to lead the global neuropathic pain market throughout the projected period. This is due to the high incidence of chronic pain and neuropathic pain disorders in the region. In addition, the existence of a large number of market rivals in the area is expected to boost market growth. 

During the projection period, the Asia Pacific market is predicted to be the fastest expanding. This is related to the region's ageing population, which is increasing the prevalence of chronic pain and neuropathic pain syndromes. Furthermore, increased knowledge regarding neuropathic pain and its treatment alternatives is likely to fuel market expansion in the area. 

Click here for full report:

https://www.pharmanucleus.com/reports/neuropathic-pain

The neuropathic pain market report provides a detailed analysis of the market, including its drivers, restraints, opportunities, and challenges. The report also provides a detailed analysis of the competitive landscape of the market. The report also provides a detailed analysis of the market segments, including their growth prospects. 

The report concludes with a SWOT analysis of the market. The SWOT analysis provides a detailed analysis of the strengths, weaknesses, opportunities, and threats of the market. The report also provides a detailed analysis of the competitive landscape of the market. 

Neuropathic Pain Market Scope and Market Size 

The neuropathic pain market is segmented by type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

By type 

The spinal cord stimulation (SCS) devices segment dominated the neuropathic pain market in 2023 due to the vast usage of these devices for various neuropathic pain indications and the wide range of the products available in the market. 

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1181

By product type 

The rechargeable segment is expected to show significant growth in the neuropathic pain market due to rechargeable devices avoiding the surgical replacement of the discharged battery in traditional devices. 

By procedure 

The invasive segment is expected to dominate the neuropathic pain market in 2023 because these devices available in the market are generally operating by invasive procedures that generally provide better efficiency for neuropathic pain. 

By technology 

The transcutaneous electrical nerve stimulation segment is expected to show significant growth in the neuropathic pain market due to transcutaneous electrical nerve stimulation being a non-invasive, inexpensive, self-administered technique to relieve pain. Due to the growing technological advancement, these devices are increasing their market size. 

By Modality 

The stationary devices segment is expected to show significant growth rate in the neuropathic pain market due to rising incidences of chronic diseases such as cancer, cardiovascular, neurovascular disease, and musculoskeletal diseases which generally include RF generators and other devices which are stationary in nature. 

By mode of purchase 

The prescription-based devices segment is expected to dominate the neuropathic pain market in 2023 due to the wide range of products available as prescription-based devices increase the market share of the segment. 

By pain type 

The peripheral neuropathy segment is expected to show the significant growth in the neuropathic pain market due to the increasing prevalence of peripheral neuropathy across the globe. 

By indication 

The diabetic neuropathy segment is likely to dominate the neuropathic pain market in 2023 due to the changi

[pharmanucleus1]

Global Disposable Medical Sensors Market Insights : Revolutionizing Healthcare

The global disposable medical sensors market was valued at USD 9.52 billion in 2022 and is projected to grow at a CAGR of 18.45% from 2023 to 2030. This growth can be attributed to technological advancements, increasing demand for health data tracking, and the need for low-cost medical devices. The rising prevalence of chronic diseases worldwide is expected to drive the demand for disposable medical sensors. According to a report by Front. Public Health in 2020, chronic non-communicable diseases (NCDs) accounted for approximately 80% of mortality among Chinese adults aged 60, with Ischemic heart disease, stroke, Chronic Obstructive Pulmonary Disease (COPD), and Type 2 diabetes being the most common conditions. The growing adoption of disposable medical sensors in healthcare settings is likely to contribute to the market's expansion in the coming years. 

Click here for full report:

https://www.pharmanucleus.com/reports/disposable-medical-sensors

Market Insights: 

In the global disposable medical sensors market, the diagnostic segment led the market in 2022, accounting for over 39.38% of the global revenue. Disposable medical sensors are widely used in diagnostic devices such as surgical tools, endoscopy equipment, spirometry devices, and medical imaging devices, enhancing their capabilities and enabling early disease detection. Advanced sensors, such as carbon nanotube-based biosensors, are being used to detect microorganisms like S. aureus and E. coli, providing faster and more accurate results at a lower cost. The integration of wireless communication and biosensors is creating growth opportunities in the diagnostic field. 

The increasing prevalence of chronic diseases and the demand for diagnostics are driving the adoption of disposable medical sensors. Diagnostic devices are crucial for monitoring symptoms and signs of chronic diseases like diabetes. Companies are developing innovative solutions to improve diagnostic capabilities, such as portable genetic material amplification systems for point-of-care molecular diagnostic detection. The patient monitoring segment is expected to have the highest compound annual growth rate (CAGR) during the forecast period. Medical sensors are utilized in patient monitoring devices like pulse oximeters and blood pressure monitors. Advancements in technology and product launches, such as next-generation monitoring biosensors by Philips, contribute to improved quality of care. 

The demand for disposable medical sensors is projected to increase due to their various advantages, leading to a rise in R&D investments and collaborations between companies. For example, Rockley Photonics Holdings Limited and Medtronic are collaborating to implement Medtronic's solutions with Rockley's Bioptx biomarker sensing technology in healthcare settings. This collaboration aims to provide real-time, non-invasive monitoring of individuals' well-being and health, enabling proactive healthcare and personalized care based on actionable data. Such initiatives are expected to drive the growth of the patient monitoring segment in the near future. 

Click here for full report:

https://www.pharmanucleus.com/reports/disposable-medical-sensors

Product Insights: 

In 2022, the biosensors segment held the largest market share, accounting for over 49.70% of the market. Biosensors are sensors designed to detect analytes by collecting biological components and utilizing a physiochemical detector. The signals from the analyte are detected, measured, and displayed on the device through associated electronics. Various types of biosensors are used, including electronic, amperometric, blood glucose, potentiometric, conduct metric, thermometric, optical, fiber optic lactate, immune, and piezoelectric biosensors. Biosensors have applications in patient monitoring and diagnostics, and the increasing demand for rapid and accurate diagnostic kits is driving the growth of biosensors. Innovations in biosensor technology are expected to lead to the development of advanced biosensors for faster diagnosis in the future. 

The image sensors segment is projected to have the highest compound annual growth rate (CAGR) during the forecast period. Image sensors convert light waves into signals to create images and find extensive use in diagnostic devices such as endoscopy equipment and electronic imaging devices. There are two types of image sensors: charge-coupled devices (CCD) and complementary metal oxide semiconductors (CMOS). CMOS image sensors are more commonly used due to their lower power consumption and faster diagnostic speed. They are primarily utilized in x-ray imaging, minimally invasive surgery, endoscopy, and ocular surgery. Technological advancements and the demand for higher resolution are expected to drive market growth in the image sensors segment.

Click here for Free sample request:

https://www.pharmanucleus.com/request-sample/1180 

Market Segmentation: 

The strip sensors segment held the largest market share in 2022, accounting for over 38.76% of the market. Strip sensors are primarily used in blood glucose monitoring, disease testing, and magnetic nanoparticles. Their dominance in the market is attributed to increasing demand and their widespread usage in diagnostic applications. Strip sensors offer the advantage of faster results, which contributes to their popularity. Furthermore, the market is driven by the growing demand for self-diagnosis and home-based medical devices. 

The ingestible sensors segment is projected to have the highest compound annual growth rate (CAGR) during the forecast period. Ingestible sensors are small chips enclosed in capsules that are swallowed, allowing for detection of any abnormalities in the body and transmission of the data to an external device. These sensors find applications in endoscopy, controlled drug delivery, and patient monitoring. The rising prevalence of chronic diseases and the need for invasive diagnostic testing are driving the growth of ingestible sensors. Additionally, the accuracy of results obtained through ingestible sensors further fuels their demand in the market. 

Due to the various advantages of ingestible sensors, the demand for these devices is anticipated to increase during the forecast period. Increasing R&D investments and collaborations between companies are also expected to propel market growth. In July 2021, according to Medtronic plc, the FDA cleared the use of two LINQ II insertable cardiac monitors with the AI AccuRhythm algorithms. When the AI AccuRhythm algorithms are made accessible on the CareLink Network later this year, all LINQ II implants in the U.S will be able to use them. 

Regional Analysis: 

North America dominated the global disposable medical sensors market in 2022, holding the largest revenue share of over 41.18%. This can be attributed to several factors, including the region's well-established healthcare infrastructure, high healthcare spending, the presence of monopolistic market players, and the rapid adoption of cutting-edge technologies. The market in North America is highly developed and is expected to be driven by the increasing uptake of patient monitoring and homecare devices for routine, ongoing, and long-term patient monitoring, which helps reduce the frequency of hospital visits. 

Favorable reimbursement policies are expected to further fuel market expansion in North America. Additionally, the rising prevalence of lifestyle-related health issues, accidents, and sports injuries contribute to the growth potential in the region. The increasing use of mobile surgery centers and the demand for effective emergency care are also anticipated to boost the market during the forecast period. Moreover, the COVID-19 pandemic has highlighted the importance of disposable medical sensors in enabling remote patient monitoring and care at home, leading to increased adoption of these devices. 

The Asia-Pacific region is projected to experience the fastest growth in the global disposable medical sensors market during the forecast period. The region witnesses a significant demand for disposable medical sensor equipment due to the increasing prevalence of cardiac disorders, particularly in countries like China and India, which also have high diabetes rates. The rising burden of diabetes in the region is driving the demand for home-based disposable medical sensors, creating new market opportunities. Additionally, the presence of major companies in the disposable medical sensors market further contributes to the region's market share and growth potential.